{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:16:34Z","timestamp":1791209794348,"version":"4.1.0"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","award":["16-07879S"],"award-info":[{"award-number":["16-07879S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"crossref","award":["15-25602A"],"award-info":[{"award-number":["15-25602A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Trace Elements in Medicine and Biology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jtemb.2016.03.010","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T10:54:02Z","timestamp":1458816842000},"page":"81-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"special_numbering":"C","title":["Iron chelation in the treatment of neurodegenerative diseases"],"prefix":"10.1016","volume":"38","author":[{"given":"Petr","family":"Dusek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Aaseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ncl.2014.09.006","article-title":"Wilson disease and other neurodegenerations with metal accumulations","volume":"33","author":"Dusek","year":"2015","journal-title":"Neurol. Clin."},{"issue":"10","key":"10.1016\/j.jtemb.2016.03.010_bib0010","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","article-title":"The role of iron in brain ageing and neurodegenerative disorders","volume":"13","author":"Ward","year":"2014","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2011.12.054","article-title":"Iron dysregulation in movement disorders","volume":"46","author":"Dusek","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jtemb.2014.12.012","article-title":"Neurodegenerative diseases and therapeutic strategies using iron chelators","volume":"31","author":"Ward","year":"2015","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0025","first-page":"59","article-title":"Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA)","volume":"11","author":"Schneider","year":"2013","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00401-008-0421-z","article-title":"The pathology of superficial siderosis of the central nervous system","volume":"116","author":"Koeppen","year":"2008","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00401-009-0615-z","article-title":"Correlation of hypointensities in susceptibility-weighted images to tissue histology in dementia patients with cerebral amyloid angiopathy: a postmortem MRI study","volume":"119","author":"Schrag","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jnnp.51.2.260","article-title":"Perivascular iron deposition and other vascular damage in multiple sclerosis","volume":"51","author":"Adams","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.jtemb.2016.03.010_bib0045","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/glia.20678","article-title":"Microglial dystrophy in the aged and Alzheimer's disease brain is associated with ferritin immunoreactivity","volume":"56","author":"Lopes","year":"2008","journal-title":"Glia"},{"issue":"9","key":"10.1016\/j.jtemb.2016.03.010_bib0050","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00018-013-1509-8","article-title":"Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration","volume":"71","author":"Andersen","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0055","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.nbd.2015.03.013","article-title":"Neurodegeneration with inflammation is accompanied by accumulation of iron and ferritin in microglia and neurons","volume":"81","author":"Thomsen","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"7","key":"10.1016\/j.jtemb.2016.03.010_bib0060","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1073\/pnas.92.7.2539","article-title":"Aceruloplasminemia molecular characterization of this disorder of iron metabolism","volume":"92","author":"Harris","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/ng571","article-title":"Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease","volume":"28","author":"Curtis","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0070","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood.V18.6.727.727","article-title":"Studies on iron absorption. I. The relationships between the rate of erythropoiesis hypoxia and iron absorption","volume":"18","author":"Mendel","year":"1961","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0075","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.nbd.2009.02.009","article-title":"A novel transferrin\/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease","volume":"34","author":"Mastroberardino","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.jtemb.2016.03.010_bib0080","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1089\/ars.2012.4885","article-title":"Lysosomal iron, iron chelation, and cell death","volume":"18","author":"Terman","year":"2013","journal-title":"Antioxid. Redox Signal."},{"issue":"7","key":"10.1016\/j.jtemb.2016.03.010_bib0085","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1089\/ars.2010.3129","article-title":"Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit","volume":"13","author":"Zhang","year":"2010","journal-title":"Antioxid. Redox Signal."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0090","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0891-5849(91)90192-6","article-title":"Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes","volume":"11","author":"Esterbauer","year":"1991","journal-title":"Free Radical Biol. Med."},{"issue":"12","key":"10.1016\/j.jtemb.2016.03.010_bib0095","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/jnen\/61.12.1069","article-title":"Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia","volume":"61","author":"Kaneko","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0100","doi-asserted-by":"crossref","first-page":"427318","DOI":"10.1155\/2014\/427318","article-title":"Oxidative stress in alzheimer's disease: why did antioxidant therapy fail?","volume":"2014","author":"Persson","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"8-9","key":"10.1016\/j.jtemb.2016.03.010_bib0105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.mad.2011.08.003","article-title":"Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain","volume":"132","author":"Lovell","year":"2011","journal-title":"Mech. Ageing Dev."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1471-4914(03)00031-5","article-title":"Protein carbonylation in human diseases","volume":"9","author":"Dalle-Donne","year":"2003","journal-title":"Trends Mol. Med."},{"issue":"1-2","key":"10.1016\/j.jtemb.2016.03.010_bib0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0009-8981(03)00003-2","article-title":"Protein carbonyl groups as biomarkers of oxidative stress","volume":"329","author":"Dalle-Donne","year":"2003","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0120","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.jtemb.2016.03.010_bib0125","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/glia.20416","article-title":"Cellular iron status influences the functional relationship between microglia and oligodendrocytes","volume":"54","author":"Zhang","year":"2006","journal-title":"Glia"},{"issue":"47","key":"10.1016\/j.jtemb.2016.03.010_bib0130","doi-asserted-by":"crossref","first-page":"44284","DOI":"10.1074\/jbc.M105343200","article-title":"Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein: a possible molecular NK between Parkinson's disease and heavy metal exposure","volume":"276","author":"Uversky","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0135","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/00001756-199903170-00011","article-title":"Oxidative stress induces amyloid-like aggregate formation of NACP\/alpha-synuclein in vitro","volume":"10","author":"Hashimoto","year":"1999","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0140","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12264-010-1117-7","article-title":"Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells","volume":"26","author":"Li","year":"2010","journal-title":"Neurosci. Bull."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tibs.2015.11.012","article-title":"Regulators of iron homeostasis: new players in metabolism, cell death, and disease","volume":"41","author":"Bogdan","year":"2016","journal-title":"Trends Biochem. Sci."},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0150","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s004010050001","article-title":"Sequestration of iron by Lewy bodies in Parkinson's disease","volume":"100","author":"Castellani","year":"2000","journal-title":"Acta Neuropathol."},{"issue":"Pt 1","key":"10.1016\/j.jtemb.2016.03.010_bib0165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/brain\/awq319","article-title":"Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease","volume":"134","author":"Jin","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.jtemb.2016.03.010_bib0170","article-title":"Basal ganglia iron in patients with multiple sclerosis measured with 7T quantitative susceptibility mapping correlates with inhibitory control","author":"Schmalbrock","year":"2015","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"24","key":"10.1016\/j.jtemb.2016.03.010_bib0175","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1212\/WNL.0000000000001679","article-title":"Dynamics of brain iron levels in multiple sclerosis: a longitudinal 3T MRI study","volume":"84","author":"Khalil","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0180","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.neurobiolaging.2014.09.013","article-title":"R2* mapping for brain iron: associations with cognition in normal aging","volume":"36","author":"Ghadery","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0185","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.neurobiolaging.2010.04.032","article-title":"Brain iron deposits are associated with general cognitive ability and cognitive aging","volume":"33","author":"Penke","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jtemb.2016.03.010_bib0190","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neuroimage.2014.10.009","article-title":"Association between increased magnetic susceptibility of deep gray matter nuclei and decreased motor function in healthy adults","volume":"105","author":"Li","year":"2015","journal-title":"Neuroimage"},{"issue":"17","key":"10.1016\/j.jtemb.2016.03.010_bib0195","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1523\/JNEUROSCI.4717-14.2015","article-title":"Striatal iron content predicts its shrinkage and changes in verbal working memory after two years in healthy adults","volume":"35","author":"Daugherty","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuroimage.2015.12.045","article-title":"Accumulation of iron in the putamen predicts its shrinkage in healthy older adults: a multi-occasion longitudinal study","volume":"128","author":"Daugherty","year":"2016","journal-title":"Neuroimage"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/neup.12149","article-title":"Aceruloplasminemia","volume":"35","author":"Miyajima","year":"2015","journal-title":"Neuropathology"},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0210","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ana.410370515","article-title":"Hereditary ceruloplasmin deficiency with hemosiderosis: a clinicopathological study of a Japanese family","volume":"37","author":"Morita","year":"1995","journal-title":"Ann. Neurol."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0215","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.21980","article-title":"High brain iron level in asymptomatic carriers of heterozygous ceruloplasmin gene mutations","volume":"23","author":"Chen","year":"2008","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0220","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.13401","article-title":"Combination-therapy with concurrent deferoxamine and deferiprone is effective in treating resistant cardiac iron-loading in aceruloplasminaemia","volume":"171","author":"Badat","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0225","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jhep.2010.04.039","article-title":"Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation","volume":"53","author":"Finkenstedt","year":"2010","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0230","first-page":"303","article-title":"Aceruloplasminaemia a family with a novel mutation and long-term therapy with deferasirox","volume":"47","author":"Lindner","year":"2015","journal-title":"Horm. Metab. Res."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0235","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000148691","article-title":"The neurological presentation of ceruloplasmin gene mutations","volume":"60","author":"McNeill","year":"2008","journal-title":"Eur. Neurol."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0240","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ana.410410318","article-title":"Use of desferrioxamine in the treatment of aceruloplasminemia","volume":"41","author":"Miyajima","year":"1997","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.jtemb.2016.03.010_bib0245","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/mds.23797","article-title":"Desferrioxamine treatment of aceruloplasminemia: long-term follow-up","volume":"26","author":"Pan","year":"2011","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0250","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jnnp.2007.120568","article-title":"Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation","volume":"79","author":"Skidmore","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"13","key":"10.1016\/j.jtemb.2016.03.010_bib0255","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2169\/internalmedicine.52.0102","article-title":"Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation","volume":"52","author":"Suzuki","year":"2013","journal-title":"Intern. Med."},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0260","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5581\/1516-8484.20110104","article-title":"Aceruloplasminemia a rare disease ? diagnosis and treatment of two cases","volume":"33","author":"Roberti Mdo","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"10","key":"10.1016\/j.jtemb.2016.03.010_bib0265","first-page":"316","article-title":"Central nervous system involvement in a rare genetic iron overload disorder","volume":"68","author":"Bethlehem","year":"2010","journal-title":"Neth. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.jtemb.2016.03.010_bib0270","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jns.2010.08.019","article-title":"Aceruloplasminemia in a Japanese woman with a novel mutation of CP gene: clinical presentations and analysis of genetic and molecular pathogenesis","volume":"298","author":"Hida","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0275","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000008091","article-title":"A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma","volume":"42","author":"Yonekawa","year":"1999","journal-title":"Eur. Neurol."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0280","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0168-8278(02)00042-9","article-title":"Aceruloplasminemia new clinical, pathophysiological and therapeutic insights","volume":"36","author":"Loreal","year":"2002","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0285","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/jnnp.2003.017434","article-title":"Clinical, molecular, and PET study of a case of aceruloplasminaemia presenting with focal cranial dyskinesia","volume":"75","author":"Haemers","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0290","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/gut.2003.030429","article-title":"Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation","volume":"53","author":"Mariani","year":"2004","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.jtemb.2016.03.010_bib0295","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.0000000000001956","article-title":"Iron chelation therapy to prevent the manifestations of aceruloplasminemia","volume":"85","author":"Bove","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jtemb.2016.03.010_bib0300","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/dme.12712","article-title":"Aceruloplasminemia presents as Type 1 diabetes in non-obese adults: a detailed case series","volume":"32","author":"Vroegindeweij","year":"2015","journal-title":"Diabet. Med."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0305","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-207541","article-title":"Aceruloplasminaemia a rare but important cause of iron overload","volume":"2015","author":"Doyle","year":"2015","journal-title":"BMJ Case Rep."},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0310","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/mds.21938","article-title":"Aceruloplasminemia a novel mutation in a family with marked phenotypic variability","volume":"23","author":"Fasano","year":"2008","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0315","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/cge.12145","article-title":"Novel ceruloplasmin mutation causing aceruloplasminemia with hepatic iron overload and diabetes without neurological symptoms","volume":"85","author":"Rusticeanu","year":"2014","journal-title":"Clin. Genet."},{"issue":"12","key":"10.1016\/j.jtemb.2016.03.010_bib0320","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/hepr.12292","article-title":"Case of presymptomatic aceruloplasminemia treated with deferasirox","volume":"44","author":"Tai","year":"2014","journal-title":"Hepatol. Res."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0325","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng572","article-title":"A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome","volume":"28","author":"Zhou","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0330","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-genom-090314-025011","article-title":"Neurodegeneration with brain iron accumulation: genetic diversity and pathophysiological mechanisms","volume":"16","author":"Meyer","year":"2015","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0335","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mdc3.12080","article-title":"7-Tesla magnetic resonance imaging for brain iron quantification in homozygous and heterozygous PANK2 mutation carriers","volume":"1","author":"Dusek","year":"2014","journal-title":"Mov. Disor. Clin. Pract."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0340","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/cmmi.1482","article-title":"Two forms of iron as an intrinsic contrast agent in the basal ganglia of PKAN patients","volume":"7","author":"Dezortova","year":"2012","journal-title":"Contrast Media Mol. Imaging"},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0345","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymgme.2015.10.012","article-title":"Pallidal neuronal apolipoprotein E in pantothenate kinase-associated neurodegeneration recapitulates ischemic injury to the globus pallidus","volume":"116","author":"Woltjer","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"9","key":"10.1016\/j.jtemb.2016.03.010_bib0350","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/mds.23751","article-title":"Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial","volume":"26","author":"Zorzi","year":"2011","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0355","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.parkreldis.2014.03.002","article-title":"Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): Results from a four years follow-up","volume":"20","author":"Cossu","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"11","key":"10.1016\/j.jtemb.2016.03.010_bib0360","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2011.043018","article-title":"A pilot trial of deferiprone for neurodegeneration with brain iron accumulation","volume":"96","author":"Abbruzzese","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0365","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.parkreldis.2015.02.006","article-title":"Pattern of disease progression in atypical form of pantothenate-kinase-associated neurodegeneration (PKAN) \u2212 Prospective study","volume":"21","author":"Tomic","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0370","doi-asserted-by":"crossref","DOI":"10.1097\/PHM.0b013e318282d209","article-title":"Treatment of classic pantothenate kinase-Associated neurodegeneration with deferiprone and intrathecal baclofen","author":"Pratini","year":"2013","journal-title":"Am. J. Phys. Med. Rehab."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0375","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00341968","article-title":"A further contribution to the knowledge of the Hallervorden-Spatz disease","volume":"212","author":"Gallyas","year":"1968","journal-title":"Arch. Psychiatr. Nervenkr."},{"issue":"17","key":"10.1016\/j.jtemb.2016.03.010_bib0380","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1212\/WNL.0000000000001511","article-title":"Cortical pencil lining in neuroferritinopathy: a diagnostic clue","volume":"84","author":"Batla","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jtemb.2016.03.010_bib0385","doi-asserted-by":"crossref","first-page":"197438","DOI":"10.1155\/2012\/197438","article-title":"MRI findings in neuroferritinopathy","volume":"2012","author":"Ohta","year":"2012","journal-title":"Neurol. Res. Int."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0390","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10048-011-0310-9","article-title":"Neuroferritinopathy a new inborn error of iron metabolism","volume":"13","author":"Keogh","year":"2012","journal-title":"Neurogenetics"},{"issue":"Pt 1","key":"10.1016\/j.jtemb.2016.03.010_bib0395","first-page":"110","article-title":"Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation","volume":"130","author":"Chinnery","year":"2007","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0400","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/mds.22435","article-title":"A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations","volume":"24","author":"Kubota","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0405","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-410502-7.00006-5","article-title":"Neuroferritinopathy","volume":"110","author":"Keogh","year":"2013","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0410","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fgene.2015.00185","article-title":"Mutations of C19orf12, coding for a transmembrane glycine zipper containing mitochondrial protein, cause mis-localization of the protein, inability to respond to oxidative stress and increased mitochondrial Ca(2)(+)","volume":"6","author":"Venco","year":"2015","journal-title":"Front. Genet."},{"issue":"12","key":"10.1016\/j.jtemb.2016.03.010_bib0415","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/acn3.116","article-title":"Brain iron quantification by MRI in mitochondrial membrane protein-associated neurodegeneration under iron-chelating therapy","volume":"1","author":"Lobel","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0420","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/mds.22002","article-title":"Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation","volume":"23","author":"Forni","year":"2008","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0425","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.parkreldis.2011.06.024","article-title":"Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation","volume":"18","author":"Kwiatkowski","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"issue":"1-2","key":"10.1016\/j.jtemb.2016.03.010_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich's ataxia: pathology, pathogenesis, and molecular genetics","volume":"303","author":"Koeppen","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0435","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fphar.2014.00130","article-title":"Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation","volume":"5","author":"Martelli","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.jtemb.2016.03.010_bib0440","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1111\/bph.12470","article-title":"Fixing frataxin: \u2018ironing out' the metabolic defect in Friedreich's ataxia","volume":"171","author":"Anzovino","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0445","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5662\/wjm.v4.i4.197","article-title":"Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases","volume":"4","author":"Kolnagou","year":"2014","journal-title":"World J. Methodol."},{"issue":"Suppl 1","key":"10.1016\/j.jtemb.2016.03.010_bib0450","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jnc.12300","article-title":"Deferiprone for the treatment of Friedreich's ataxia","volume":"126","author":"Pandolfo","year":"2013","journal-title":"J. Neurochem."},{"issue":"1-2","key":"10.1016\/j.jtemb.2016.03.010_bib0455","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.brainresrev.2011.04.001","article-title":"Friedreich's ataxia: past, present and future","volume":"67","author":"Marmolino","year":"2011","journal-title":"Brain Res. Rev."},{"issue":"8","key":"10.1016\/j.jtemb.2016.03.010_bib0460","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/hmg\/ddu745","article-title":"Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia","volume":"24","author":"Igoillo-Esteve","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0465","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.freeradbiomed.2015.03.014","article-title":"Mitoferrin modulates iron toxicity in a Drosophila model of Friedreich's ataxia","volume":"85","author":"Navarro","year":"2015","journal-title":"Free Radical Biol. Med."},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0470","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/NEN.0b013e31827e5762","article-title":"Friedreich ataxia: neuropathology revised","volume":"72","author":"Koeppen","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0475","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/14734220600913246","article-title":"Iron and iron-responsive proteins in the cardiomyopathy of Friedreich's ataxia","volume":"5","author":"Michael","year":"2006","journal-title":"Cerebellum"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0480","doi-asserted-by":"crossref","first-page":"e0116396","DOI":"10.1371\/journal.pone.0116396","article-title":"The pathogenesis of cardiomyopathy in Friedreich ataxia","volume":"10","author":"Koeppen","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.jtemb.2016.03.010_bib0485","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.amjcard.2012.08.018","article-title":"Relation of cytosolic iron excess to cardiomyopathy of Friedreich's ataxia","volume":"110","author":"Ramirez","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"8","key":"10.1016\/j.jtemb.2016.03.010_bib0490","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/ene.12448","article-title":"Dentate nuclei T2 relaxometry is a reliable neuroimaging marker in Friedreich's ataxia","volume":"21","author":"Bonilha da Silva","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0495","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nicl.2014.08.018","article-title":"Cerebellar pathology in Friedreich's ataxia: atrophied dentate nuclei with normal iron content","volume":"6","author":"Solbach","year":"2014","journal-title":"Neuroimage Clin."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0500","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2051-5960-1-26","article-title":"Friedreich ataxia: metal dysmetabolism in dorsal root ganglia","volume":"1","author":"Koeppen","year":"2013","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0505","doi-asserted-by":"crossref","DOI":"10.1007\/s12311-012-0383-5","article-title":"Friedreich\u2019s ataxia causes redistribution of iron, copper, and zinc in the dentate nucleus","author":"Koeppen","year":"2012","journal-title":"Cerebellum"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0510","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12311-010-0212-7","article-title":"Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia","volume":"10","author":"Velasco-Sanchez","year":"2011","journal-title":"Cerebellum"},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0520","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ana.24248","article-title":"Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial","volume":"76","author":"Pandolfo","year":"2014","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0525","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ane.12141","article-title":"Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia\u2014open-label trial","volume":"129","author":"Arpa","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0530","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/mds.870090509","article-title":"Superficial hemosiderosis of the central nervous system","volume":"9","author":"River","year":"1994","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.jtemb.2016.03.010_bib0535","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s10072-014-1709-5","article-title":"CSF biomarkers in superficial siderosis: a new tool for diagnosis and evaluation of therapeutic efficacy of deferiprone\u2013a case report","volume":"35","author":"Schirinzi","year":"2014","journal-title":"Neurol. Sci."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0540","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ncpneuro0356","article-title":"Superficial siderosis: a case report and review of the literature","volume":"3","author":"Levy","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"issue":"3\u20134","key":"10.1016\/j.jtemb.2016.03.010_bib0545","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000442299","article-title":"Cortical superficial siderosis in memory clinic patients: further evidence for underlying cerebral amyloid angiopathy","volume":"41","author":"Charidimou","year":"2016","journal-title":"Cerebrovasc. Dis."},{"issue":"8","key":"10.1016\/j.jtemb.2016.03.010_bib0550","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1212\/WNL.0000000000001288","article-title":"Cortical superficial siderosis: a marker of vascular amyloid in patients with cognitive impairment","volume":"84","author":"Na","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0555","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00005072-198805000-00005","article-title":"Brain hemosiderin and superficial siderosis of the central nervous system","volume":"47","author":"Koeppen","year":"1988","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0560","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/019459989210700111","article-title":"Superficial siderosis of the central nervous system: a neglected cause of sensorineural hearing loss","volume":"107","author":"Parnes","year":"1992","journal-title":"Otolaryngol. Head Neck Surg."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0565","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.3174\/ajnr.A2331","article-title":"Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis","volume":"32","author":"Levy","year":"2011","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0570","doi-asserted-by":"crossref","first-page":"E99","DOI":"10.3174\/ajnr.A3186","article-title":"Update on a patient with superficial siderosis on deferiprone","volume":"33","author":"Levy","year":"2012","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0575","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009916","article-title":"Treatment of superficial siderosis with iron chelation therapy","volume":"2013","author":"Cummins","year":"2013","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0580","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-010099","article-title":"Agranulocytosis with deferiprone treatment of superficial siderosis","volume":"2013","author":"Huprikar","year":"2013","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0585","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1161\/STROKEAHA.111.628032","article-title":"Pilot safety trial of deferiprone in 10 subjects with superficial siderosis","volume":"43","author":"Levy","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.jtemb.2016.03.010_bib0590","article-title":"Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics","author":"Belaidi","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0595","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jtemb.2014.05.007","article-title":"The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases","volume":"31","author":"Dusek","year":"2015","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0600","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3174\/ajnr.A4260","article-title":"Usefulness of quantitative susceptibility mapping for the diagnosis of Parkinson disease","volume":"36","author":"Murakami","year":"2015","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"11","key":"10.1016\/j.jtemb.2016.03.010_bib0605","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1002\/hbm.22928","article-title":"Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping","volume":"36","author":"He","year":"2015","journal-title":"Hum. Brain Mapp."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0610","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/mds.26417","article-title":"Quantitative susceptibility mapping of the midbrain in Parkinson's disease","volume":"31","author":"Du","year":"2016","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0615","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.mri.2015.02.021","article-title":"Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2","volume":"33","author":"Barbosa","year":"2015","journal-title":"Magn. Reson. Imaging"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0620","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jmri.22752","article-title":"High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease","volume":"35","author":"Lotfipour","year":"2012","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.jtemb.2016.03.010_bib0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2015.09.012","article-title":"Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease","author":"Zucca","year":"2015","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0630","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12640-009-9140-z","article-title":"Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease","volume":"19","author":"Zhang","year":"2011","journal-title":"Neurotox. Res."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0635","first-page":"277","article-title":"Iron histochemistry of the substantia nigra in Parkinson's disease","volume":"3","author":"Morris","year":"1994","journal-title":"Neurodegeneration"},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0640","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000332954","article-title":"A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration","volume":"20","author":"Li","year":"2012","journal-title":"Neurosignals"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0645","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.mp.4001937","article-title":"The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element","volume":"12","author":"Friedlich","year":"2007","journal-title":"Mol. Psychiatry"},{"issue":"9","key":"10.1016\/j.jtemb.2016.03.010_bib0650","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/WNR.0b013e328354a1f0","article-title":"alpha-Synuclein expression is modulated at the translational level by iron","volume":"23","author":"Febbraro","year":"2012","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0655","doi-asserted-by":"crossref","first-page":"e15814","DOI":"10.1371\/journal.pone.0015814","article-title":"Alpha-synuclein is a cellular ferrireductase","volume":"6","author":"Davies","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0660","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1471-4159.2010.07132.x","article-title":"The relevance of iron in the pathogenesis of Parkinson's disease","volume":"118","author":"Sian-Hulsmann","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0665","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2013.01.017","article-title":"Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators","volume":"62","author":"Weinreb","year":"2013","journal-title":"Free Radical Biol. Med."},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0670","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/ars.2013.5593","article-title":"Targeting chelatable iron as a therapeutic modality in Parkinson's disease","volume":"21","author":"Devos","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0675","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12883-015-0331-3","article-title":"Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease","volume":"15","author":"Grolez","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0680","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2015.08.007","article-title":"The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: two sides of the same coin","volume":"81","author":"Peters","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0685","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pneurobio.2011.05.001","article-title":"Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis: some insight on the influence of citation bias on scientific opinion","volume":"94","author":"Schrag","year":"2011","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0690","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/nbm.3247","article-title":"The effect of iron in MRI and transverse relaxation of amyloid-beta plaques in Alzheimer's disease","volume":"28","author":"Meadowcroft","year":"2015","journal-title":"NMR Biomed."},{"issue":"9","key":"10.1016\/j.jtemb.2016.03.010_bib0695","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/j.neurobiolaging.2015.05.022","article-title":"Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease","volume":"36","author":"Zeineh","year":"2015","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0700","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jnr.490310111","article-title":"A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains","volume":"31","author":"Connor","year":"1992","journal-title":"J. Neurosci. Res."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0705","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/JAD-2010-101503","article-title":"Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease","volume":"24","author":"Schrag","year":"2011","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0710","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02260965","article-title":"Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy","volume":"7","author":"Kuiper","year":"1994","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0715","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1038\/ncomms7760","article-title":"Alzheimer's Disease Neuroimaging I. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE","volume":"6","author":"Ayton","year":"2015","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0720","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1021\/ic402406g","article-title":"Evidence of redox-active iron formation following aggregation of ferrihydrite and the Alzheimer's disease peptide beta-amyloid","volume":"53","author":"Everett","year":"2014","journal-title":"Inorg. Chem."},{"issue":"95","key":"10.1016\/j.jtemb.2016.03.010_bib0725","doi-asserted-by":"crossref","first-page":"20140165","DOI":"10.1098\/rsif.2014.0165","article-title":"Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide beta-amyloid (1\u201342)","volume":"11","author":"Everett","year":"2014","journal-title":"J. R. Soc. Interface"},{"issue":"8753","key":"10.1016\/j.jtemb.2016.03.010_bib0730","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","article-title":"Intramuscular desferrioxamine in patients with Alzheimer's disease","volume":"337","author":"Crapper McLachlan","year":"1991","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jtemb.2016.03.010_bib0735","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A beta amyloid deposition and toxicity in Alzheimer disease\u2014a pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch. Neurol."},{"issue":"9","key":"10.1016\/j.jtemb.2016.03.010_bib0740","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0745","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3233\/JAD-2010-1390","article-title":"PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses","volume":"20","author":"Faux","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0750","doi-asserted-by":"crossref","DOI":"10.1002\/ana.23974","article-title":"Iron and neurodegeneration in the multiple sclerosis brain","author":"Hametner","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0755","doi-asserted-by":"crossref","first-page":"725370","DOI":"10.1155\/2015\/725370","article-title":"Inflammation Iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis","volume":"2015","author":"Haider","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"8","key":"10.1016\/j.jtemb.2016.03.010_bib0760","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneurol.2014.118","article-title":"Iron in multiple sclerosis: roles in neurodegeneration and repair","volume":"10","author":"Stephenson","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0765","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1471-4159.2011.07536.x","article-title":"Pathogenic implications of iron accumulation in multiple sclerosis","volume":"120","author":"Williams","year":"2012","journal-title":"J. Neurochem."},{"issue":"Suppl. 2","key":"10.1016\/j.jtemb.2016.03.010_bib0770","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.neurobiolaging.2014.03.039","article-title":"Iron and multiple sclerosis","volume":"35","author":"Stankiewicz","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0775","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17010100","article-title":"Iron in multiple sclerosis and its noninvasive imaging with quantitative susceptibility mapping","volume":"17","author":"Stuber","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0780","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/jmri.24644","article-title":"Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: a 7 Tesla MRI study","volume":"41","author":"Blazejewska","year":"2015","journal-title":"J. Magn. Reson. Imaging"},{"issue":"7","key":"10.1016\/j.jtemb.2016.03.010_bib0785","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1177\/1352458512465135","article-title":"Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome","volume":"19","author":"Al-Radaideh","year":"2013","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0790","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3174\/ajnr.A3998","article-title":"Iron and volume in the deep gray matter: association with cognitive impairment in multiple sclerosis","volume":"36","author":"Modica","year":"2015","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"13","key":"10.1016\/j.jtemb.2016.03.010_bib0795","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1177\/1352458514531085","article-title":"Determinants of iron accumulation in deep grey matter of multiple sclerosis patients","volume":"20","author":"Ropele","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0800","doi-asserted-by":"crossref","DOI":"10.1002\/jmri.25144","article-title":"Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM)","author":"Zhang","year":"2016","journal-title":"J. Magn. Reson. Imaging"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0805","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1148\/radiol.13130353","article-title":"Quantitative susceptibility mapping of multiple sclerosis lesions at various ages","volume":"271","author":"Chen","year":"2014","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.jtemb.2016.03.010_bib0810","doi-asserted-by":"crossref","first-page":"e0128386","DOI":"10.1371\/journal.pone.0128386","article-title":"Magnetic resonance phase alterations in multiple sclerosis patients with short and long disease duration","volume":"10","author":"Bozin","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jtemb.2016.03.010_bib0815","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/mrm.25420","article-title":"Quantitative susceptibility mapping (QSM) of white matter multiple sclerosis lesions: interpreting positive susceptibility and the presence of iron","volume":"74","author":"Wisnieff","year":"2015","journal-title":"Magn. Reson. Med."},{"issue":"12","key":"10.1016\/j.jtemb.2016.03.010_bib0820","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/jnnp-2014-307712","article-title":"Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron","volume":"85","author":"Haider","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0825","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jnr.490270421","article-title":"Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains","volume":"27","author":"Connor","year":"1990","journal-title":"J. Neurosci. Res."},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0830","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/glia.20784","article-title":"Oligodendrocytes and myelination: the role of iron","volume":"57","author":"Todorich","year":"2009","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0835","doi-asserted-by":"crossref","first-page":"e57573","DOI":"10.1371\/journal.pone.0057573","article-title":"Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions","volume":"8","author":"Mehta","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtemb.2016.03.010_bib0840","doi-asserted-by":"crossref","DOI":"10.1038\/mp.2015.192","article-title":"Brain iron accumulation affects myelin-related molecular systems implicated in a rare neurogenetic disease family with neuropsychiatric features","author":"Heidari","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0845","doi-asserted-by":"crossref","first-page":"e00136","DOI":"10.1042\/AN20130037","article-title":"Iron chelation and multiple sclerosis","volume":"6","author":"Weigel","year":"2014","journal-title":"ASN Neuro"},{"key":"10.1016\/j.jtemb.2016.03.010_bib0850","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nbd.2013.01.012","article-title":"Copper\/zinc chelation by clioquinol reduces spinal cord white matter damage and behavioral deficits in a murine MOG-induced multiple sclerosis model","volume":"54","author":"Choi","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0855","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.explore.2013.04.003","article-title":"Personalization of multiple sclerosis treatments: using the chelation therapy approach","volume":"9","author":"Zanella","year":"2013","journal-title":"Explore (NY)"},{"issue":"6","key":"10.1016\/j.jtemb.2016.03.010_bib0860","first-page":"365","article-title":"A trial of deferoxamine (desferal) in the treatment of multiple-sclerosis \u2212 a pilot-study","volume":"26","author":"Norstrand","year":"1989","journal-title":"Clin. Trials J."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0865","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/135245859600200306","article-title":"Desferrioxamine in chronic progressive multiple sclerosis: a pilot study","volume":"2","author":"Lynch","year":"1996","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.jtemb.2016.03.010_bib0870","first-page":"865","article-title":"A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis","volume":"46","author":"Lynch","year":"2000","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0875","first-page":"1","article-title":"Trace metals in the brain and in Wilson's disease","volume":"21","author":"Cumings","year":"1968","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.jtemb.2016.03.010_bib0880","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00401-005-1061-1","article-title":"Extensive cortico-subcortical lesions in Wilson's disease: clinico-pathological study of two cases","volume":"110","author":"Mikol","year":"2005","journal-title":"Acta Neuropathol."},{"issue":"8566","key":"10.1016\/j.jtemb.2016.03.010_bib0885","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(87)92598-0","article-title":"Brain copper in Wilson's disease","volume":"2","author":"Walshe","year":"1987","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0890","first-page":"197","article-title":"Chelation treatment of neurological Wilson's disease","volume":"86","author":"Walshe","year":"1993","journal-title":"Q. J. Med."},{"issue":"3","key":"10.1016\/j.jtemb.2016.03.010_bib0895","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1139\/Y09-128","article-title":"Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation","volume":"88","author":"Kakhlon","year":"2010","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0900","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jtemb.2014.10.001","article-title":"Chelation in metal intoxication\u2013Principles and paradigms","volume":"31","author":"Aaseth","year":"2015","journal-title":"J. Trace Elem. Med. Biol."},{"issue":"1","key":"10.1016\/j.jtemb.2016.03.010_bib0905","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1365-2141.2003.04240.x","article-title":"Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients","volume":"121","author":"Mourad","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.jtemb.2016.03.010_bib0910","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/pbc.25533","article-title":"The deferiprone and deferasirox combination is efficacious in iron overloaded patients with beta-thalassemia major: a prospective, single center, open-label study","volume":"62","author":"Totadri","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jtemb.2016.03.010_bib0915","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphar.2013.00167","article-title":"Regional siderosis: a new challenge for iron chelation therapy","volume":"4","author":"Cabantchik","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jtemb.2016.03.010_bib0920","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1750-1172-7-66","article-title":"An international registry for neurodegeneration with brain iron accumulation","volume":"7","author":"Kalman","year":"2012","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Journal of Trace Elements in Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0946672X16300475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0946672X16300475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T23:16:50Z","timestamp":1748819810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0946672X16300475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":184,"alternative-id":["S0946672X16300475"],"URL":"https:\/\/doi.org\/10.1016\/j.jtemb.2016.03.010","relation":{},"ISSN":["0946-672X"],"issn-type":[{"value":"0946-672X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iron chelation in the treatment of neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Trace Elements in Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtemb.2016.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}